| Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (NCT05257408) | Corcept Therapeutics | 2022-06-29 |
| Preoperative Systemic Therapy for Colorectal Cancer Peritoneal Metastases (NCT05353582) | Sun Yat-sen University | 2022-06-01 |
| A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors (NCT05194072) | Seagen, a wholly owned subsidiary of Pfizer | 2022-01-12 |
| MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO) (NCT04111978) | Swiss GO Trial Group | 2020-11-05 |
| Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery (NCT04498117) | CanariaBio Inc. | 2020-08-25 |
| An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer (NCT01932125) | Hoffmann-La Roche | 2018-12-05 |
| Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy (NCT03593681) | Boston Scientific Corporation | 2018-08-27 |
| EDMONd - Elemental Diet in Bowel Obstruction (NCT03150992) | Royal Surrey County Hospital NHS Foundation Trust | 2017-07-19 |
| Development of a Cinical and Biological Database in Ovarian, Fallopian Tube and Peritoneal Cancers (NCT03976999) | Institut du Cancer de Montpellier - Val d'Aurelle | 2017-07-05 |
| Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases (NCT02758951) | Koen Rovers | 2017-06-01 |
| A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT03038100) | Hoffmann-La Roche | 2017-03-08 |
| Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer. (NCT02903771) | Kazia Therapeutics Limited | 2016-12-05 |
| Treatment of Peritoneal Carcinomatosis With Pressurized IntraPeritoneal Aerosol Chemotherapy - (NCT03287375) | Michael Bau Mortensen | 2016-12-01 |
| Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors (NCT02658214) | AstraZeneca | 2016-04-28 |
| PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer (NCT02571725) | New Mexico Cancer Research Alliance | 2016-02-23 |
| Effect of Outpatient Symptom Management on Gynecologic Oncology Patients Receiving Chemotherapy (NCT02786524) | University of Michigan | 2016-02-15 |
| DNA Single Nucleotide Polymorphisms as Predictors of Toxicity (NCT02478476) | OvaGene Oncology, Inc. | 2015-07-01 |
| Palliative Care in Improving Quality of Life in Patients With High Risk Primary or Recurrent Gynecologic Malignancies (NCT02578888) | Albert Einstein College of Medicine | 2015-04-01 |
| Adjuvant HIPEC in High Risk Colon Cancer (NCT02231086) | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 2015-03-01 |
| HIPEC For Peritoneal Surface Malignancies Including Carcinomatosis or Sarcomatosis - Data Registry (NCT02082886) | Edward-Elmhurst Health System | 2014-02-01 |
| Local mEHT + TCM Versus Intraperitoneal Chemoinfusion in Treatment of Malignant Ascites: Phase II RCT (NCT02638051) | Galenic Research Institute Ltd | 2014-01-01 |
| A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (NCT01846611) | Janssen Research & Development, LLC | 2013-10-16 |
| Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer (NCT01681368) | National Cancer Institute (NCI) | 2012-08-15 |
| An Observational Study of Avastin (Bevacizumab) in Combination With Carboplatin/Paclitaxel in First Line in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (OTILIA) (NCT01697488) | Hoffmann-La Roche | 2012-02-02 |
| A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors (NCT01478685) | Celgene | 2011-11-29 |
| Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer (NCT01462890) | AGO Study Group | 2011-11-01 |
| Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy (NCT01384253) | Orano Med LLC | 2011-07-01 |
| BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer (NCT01314105) | Boehringer Ingelheim | 2011-03-15 |
| Comparison of Traditional and Echocardiography Guided Fluid Management During Cytoreductive Surgery With HIPEC (NCT01225757) | University of Nebraska | 2010-11-01 |
| LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer (NCT01015118) | Boehringer Ingelheim | 2009-11-17 |
| A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers (NCT00698451) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2008-08-01 |
| Pharmacokinetic, Safety and Efficacy Study of Nanoparticle Paclitaxel in Patients With Peritoneal Cancers (NCT00666991) | CritiTech, Inc. | 2008-07-01 |
| A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer (NCT00516841) | Facet Biotech | 2007-08-01 |
| Quality of Life Study for Pediatric and Adult Patients Undergoing Hyperthermic Peritoneal Perfusion With Cisplatin (NCT00502177) | M.D. Anderson Cancer Center | 2007-06-19 |
| Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT00445549) | National Cancer Institute (NCI) | 2007-01-01 |
| ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma (NCT00407407) | Celgene | 2006-11-01 |
| OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer (NCT00382811) | MEI Pharma, Inc. | 2006-10-01 |
| A Phase II Study of Surgical Debulking With Peritonectomy and Biweekly Intraperitoneal 5FU With Systemic Oxaliplatin/5FU/Leucovorin in Patients With Pseudomyxoma Peritonei or Peritoneal Carcinomatosis (NCT00352755) | Washington University School of Medicine | 2006-05-01 |
| Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas (NCT00443196) | Pierian Biosciences | 2006-03-01 |
| Use of FACT-GOG/NTX Questionnaire in Peripheral Neurotoxicity & Validation of a French Version of This Questionnaire (NCT00517621) | ARCAGY/ GINECO GROUP | 2006-02-01 |
| Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube Cancers (NCT00086567) | National Cancer Institute (NCI) | 2005-12-12 |
| Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer (NCT00262990) | Novartis Pharmaceuticals | 2005-11-01 |
| Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis (NCT00332696) | Novartis Pharmaceuticals | 2005-09-01 |
| Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer (NCT00317772) | M.D. Anderson Cancer Center | 2004-09-02 |
| Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer (NCT00288275) | Precision Therapeutics | 2004-07-01 |
| Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients (NCT00189345) | AGO Study Group | 2004-05-01 |
| Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube Cancer (NCT00074867) | Pfizer | 2003-10-01 |
| Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis (NCT00216372) | Ipsen | 2003-09-01 |
| Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune Response (NCT00103545) | AGO Study Group | 2003-07-01 |
| Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma (NCT00183794) | University of Southern California | 2002-11-01 |
| An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy (NCT00191646) | Eli Lilly and Company | 2002-10-01 |
| A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer. (NCT00191607) | Eli Lilly and Company | 2002-07-01 |
| EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer (NCT00035100) | Novartis Pharmaceuticals | 2001-09-01 |
| Phase I Study of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Escalating Dose I.P. Platinum for Gastrointestinal Peritoneal Carcinomatosis (NCT00001332) | National Cancer Institute (NCI) | 1992-12-01 |